2024年10月31日 · Since the FDA approval of Novo Nordisk’s Wegovy as a treatment for chronic weight management in 2021, followed by the approval of Ozempic the next year, demand for GLP-1 agonist drugs has rapidly grown.

2024年12月17日 · “The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline.”

2024年11月25日 · (Image: Getty/Spainter_vfx) Q: What trends do you see shaping eCOA/ePRO in the next year? SR: Personalization and adaptability are big ones.Patients want tailored experiences, so platforms will need to adapt to individual needs — whether that’s through language options, integration with personal devices, or customized notifications.

At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch of a state-of-the-art nanomedicines GMP facility in Oss, Netherlands.

2024年8月29日 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.

2024年7月23日 · Rusan Pharma Private Limited has announced that its active pharmaceutical ingredient (API) manufacturing facility in Ankleshwar, Gujarat, has been granted Good Manufacturing Practice (GMP) approval by the FDA.

2024年11月7日 · Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to its TransCon technology platform for the development, manufacturing and commercialization of Novo’s products in metabolic diseases, including obesity and type 2 diabetes.

2024年12月12日 · Noema Pharma has announced an extension of its series B financing round, bringing the total raised up to $147 million (CHF 130 million). The round extension has seen venture capital firm EQT Life Sciences join the Swiss company’s existing investors, which include Forbion, Jeito Capital, Sofinnova Partners, and Gilde Healthcare among others.

2024年10月24日 · The increasing integration of medical radioisotopes with diagnostic and molecular imaging as well as the rise of personalized medicine is spurring the growth of the global market for these products, which was valued at $5.1 billion in 2022 and is expected to soar by 8.8% per year to $11.4 billion by 2032. NorthStar’s peers in the field include Nordion, Isotopen Technologien München (ITM ...

2024年11月4日 · The pharmaceutical industry is witnessing a shift as small molecule drugs become increasingly complex and potent. Advances in medicinal chemistry are driving the development of more sophisticated compounds, often with highly targeted mechanisms of action.